| name | drug-interaction-checker |
| description | Checks for potential drug-drug interactions (DDIs) between a list of medications. |
| measurable_outcome | Execute skill workflow successfully with valid output within 15 minutes. |
| allowed-tools | ["read_file","run_shell_command"] |
Drug-Drug Interaction (DDI) Checker
This skill analyzes a list of medications to identify known interactions, focusing on safety and contraindications.
When to Use This Skill
- Reviewing patient medication lists.
- Prescribing new medications.
- Pharmacovigilance monitoring.
Core Capabilities
- Interaction Detection: Identifies pairs of drugs with known interactions.
- Severity Grading: Classifies interactions as Minor, Moderate, or Major.
- Clinical Recommendations: Provides actionable advice (e.g., "Monitor K+ levels").
- LLM-vs-Reference DDI Checking Caution: For antiseizure medication interaction checks, use LLM output only as a draft that must be verified against Lexicomp/Drugs.com-style DDI references. Reconcile severity/category differences across sources, document any finite iterative prompting limit and remaining disagreements, and route unresolved or clinically significant interactions to pharmacist or qualified clinician review before clinical use.
- LLM DDI Evidence Hierarchy and Validation Checklist: For LLM-generated DDI answers, rank curated references such as Lexicomp or Drugs.com above model-generated content, use antiseizure medication DDIs as a stress case when applicable, validate whether the answer identifies the interacting drug pair, mechanism, severity/category, clinical recommendation, and source agreement/disagreement, and retain iterative prompt audit logs showing each prompt, answer revision, and comparison outcome against the curated reference.
- Antiseizure Medication DDI Evaluation: For antiseizure medication interaction checks, compare LLM outputs with Lexicomp and Drugs.com references, reconcile interaction severity/category differences before presenting conclusions, set and report a finite iterative prompting limit, and require pharmacist or qualified clinician verification before clinical use.
- Authoritative ASM DDI Review: When evaluating antiseizure medication DDIs, classify interaction severity from authoritative references such as Lexicomp, cite the evidence source used for each clinically relevant interaction, apply iterative prompting only as a bounded safeguard to improve LLM output, and require pharmacist review before recommendations are used for patient care.
- ASM DDI Benchmarking Guidance: When benchmarking antiseizure medication DDI checks, compare outputs against authoritative references such as Lexicomp and Drugs.com, audit severity agreement and missing interactions, treat iterative prompting as a risk surface that may change answers without proving correctness, and require pharmacist review for unresolved, missing, or clinically significant interaction findings.
- ASM DDI Benchmark Source Priority: For antiseizure medication DDI benchmarking against Lexicomp and Drugs.com, treat curated references as higher priority than LLM outputs, define the iterative prompting cap before review, reconcile severity discrepancies explicitly, and warn users whenever an LLM answer conflicts with curated reference findings.
- LLM-Based DDI Benchmark Caution: For LLM-based DDI checks, use antiseizure medication interactions as a high-risk benchmark example; require source grounding against authoritative references such as Lexicomp or product labeling, reproducible iterative prompt checks, severity classification, and pharmacist review before clinical use.
- Lexicomp-Centered LLM DDI Benchmarking: When benchmarking LLM drug-drug interaction responses or consumer reference outputs for antiseizure medications, compare each response against an authoritative reference such as Lexicomp, set a finite iterative prompting limit before testing, track whether each iteration changes the interaction pair, severity/category, mechanism, recommendation, or source agreement, and escalate to pharmacist or qualified clinician review whenever Lexicomp, Drugs.com-style references, and LLM outputs disagree.
- ASM DDI Reference Comparison and Citation Control: For antiseizure medication DDI evaluation, compare LLM responses with curated references such as Lexicomp and Drugs.com, normalize interaction severity labels before reporting agreement or disagreement, cite the reference used for each clinically relevant interaction, state the bounded iterative prompting limit, and require pharmacist oversight before clinical use.
- Lexicomp/Drugs.com-Anchored ASM Benchmark Workflow: For antiseizure medication DDI benchmarking, anchor comparisons to Lexicomp and Drugs.com where available, predefine and report the iterative prompting limit, check agreement in severity-class assignments before accepting outputs, require citations for each clinically relevant interaction, and keep pharmacist review mandatory before any clinical use.
- LLM DDI Confidence Threshold Gate: For LLM-based drug-drug interaction checks, benchmark answers against trusted references such as Lexicomp and Drugs.com, treat antiseizure medication interactions as edge cases requiring extra scrutiny, predefine confidence thresholds for accepting, flagging, or rejecting model outputs, treat iterative prompting as a potential answer-drift risk rather than proof of correctness, and require pharmacist review before any clinical recommendation is used.
- Antiseizure DDI Comparative Review: For antiseizure medication DDI evaluations, treat Lexicomp as the primary comparator and Drugs.com as a secondary comparator when available; normalize severity labels before judging agreement with LLM output, document any iterative prompting steps as exploratory caveats rather than validation, and require pharmacist review before relying on the final interaction assessment.
- ASM Interaction Prompt-Sensitivity Safeguards: For antiseizure medication interaction checks, use an authoritative compendium as the benchmark reference, test and report whether iterative prompting changes the result, evaluate interaction severity separately from management advice, cite the supporting evidence, and never offer reassurance produced through iterative prompting unless the benchmark evidence supports it.
- Source-Dated ASM DDI Benchmarking: Benchmark antiseizure-medication DDI outputs against authoritative references such as Lexicomp, recording each source and access/update date; use a predefined, finite iterative-prompting protocol; extract interaction severity and mechanism separately; document disagreements among the LLM, Drugs.com, and Lexicomp without resolving them by model consensus; and escalate unresolved, clinically significant, or source-date-sensitive findings to a pharmacist before clinical use.
- Validated ASM DDI Evaluation: Evaluate antiseizure-medication DDI outputs against authoritative references such as Lexicomp, test sensitivity to iterative prompting, verify interaction severity and mechanism, check for omitted interactions, and never use LLM output as a replacement for a validated interaction database.
- ASM DDI Validation and Review Gates: Validate antiseizure-medication interaction cases against authoritative drug-information references such as Lexicomp, use predefined iterative-prompting controls, measure and report agreement or disagreement for severity and mechanism separately, and require both a supporting citation and pharmacist review before accepting any clinically relevant output.
- ASM DDI Benchmark Procedure: Benchmark antiseizure-medication interactions against an authoritative reference such as Lexicomp; score severity and mechanism agreement separately; repeat the evaluation with bounded iterative prompts to identify answer sensitivity; verify that every interaction claim has a supporting citation; and mandatorily escalate uncertain, conflicting, or unsupported interactions to a pharmacist or qualified clinician.
- Comparative DDI Benchmark Audit: Compare LLM antiseizure-medication interaction assessments with authoritative compendia such as Lexicomp and Drugs.com; score severity and mechanism agreement separately; test and record sensitivity to bounded iterative prompting; track omitted interactions; verify supporting citations; and escalate conflicting source findings to a pharmacist or qualified clinician.
- PubMed 41994367 ASM DDI Benchmarking: For antiseizure medication DDI benchmarks informed by the 2026 cross-sectional comparison of LLMs and Drugs.com versus Lexicomp, compare generated answers against authoritative databases rather than model consensus, report severity-classification agreement or disagreement, state bounded iterative prompting limits, and require pharmacist review before clinical interpretation.
- ASM DDI Omission and Recommendation Audit: When checking antiseizure medication DDIs, compare LLM outputs against authoritative references such as Lexicomp, capture omissions in severity, mechanism, or evidence support, preserve iterative prompt audit trails, and avoid clinical recommendations that are not supported by the benchmark reference.
- Authoritative DDI Evaluation and Prompt Testing: Prioritize validated interaction databases such as Lexicomp over Drugs.com and LLM output; assess severity and mechanism agreement separately, treat omitted interactions as false-negative risks, and use bounded iterative prompting to test answer stability rather than establish correctness.
- Authoritative Benchmark and Escalation Record: Benchmark antiseizure-medication examples against an authoritative reference such as Lexicomp; run bounded iterative-prompt sensitivity testing; report interaction severity and mechanism as separate fields; and explicitly escalate to a pharmacist or qualified clinician whenever evidence conflicts across sources or is incomplete.
- Benchmark-Driven DDI Verification: Normalize medication names and formulations before comparison; verify each DDI against an authoritative reference such as Lexicomp; report interaction-severity concordance; cite the evidence supporting each clinically relevant finding; predefine and log finite prompt iterations; escalate conflicting, incomplete, or unsupported findings to a pharmacist or qualified clinician; and never treat repeated prompting or repeated model agreement as independent confirmation.
- Authoritative ASM Interaction Benchmarking: Benchmark antiseizure-medication interaction cases against Lexicomp-style authoritative references; test and record prompt sensitivity with bounded iterative prompting; report severity concordance; verify every supporting citation; and mandatorily escalate conflicting results to a pharmacist or qualified clinician.
- ASM DDI Source Hierarchy and Discordance Review: Evaluate antiseizure-medication DDIs using Lexicomp or another authoritative reference as the primary comparator, secondary references such as Drugs.com as corroboration, and LLM output as unvalidated; report severity and mechanism agreement separately, test and document stability across bounded iterative prompts, disclose uncertainty and source discordance, and require pharmacist review for every discordant result before clinical use.
- ASM DDI Validation, Agreement Scoring, and Escalation: Validate each antiseizure-medication DDI against authoritative references using a source hierarchy that prioritizes Lexicomp or another validated compendium, treats Drugs.com as a secondary comparator, and treats LLM output as unvalidated; score severity and mechanism agreement separately; use predefined, bounded iterative prompts to test answer sensitivity; and mandatorily escalate uncertain, unsupported, or discordant interactions to a pharmacist or qualified clinician.
- Reference-Standard DDI Evaluation: Evaluate DDI outputs against curated databases using an explicit source hierarchy; measure interaction detection, severity agreement, and unsafe omissions; and test whether findings remain stable across predefined, bounded iterative prompting strategies.
- ASM DDI Source-Hierarchy and Recommendation-Stability Gate: Verify every antiseizure-medication interaction against an authoritative interaction database, using Lexicomp as the primary comparator and Drugs.com as a secondary comparator where available; track whether the identified interaction, severity, or management advice changes across each bounded prompt iteration; assess severity separately from management advice; and escalate uncertain or high-risk combinations to a pharmacist before clinical use.
- ASM DDI Benchmarking and Provenance Audit: Benchmark antiseizure-medication DDI findings against Lexicomp as the reference standard, using database-backed sources ahead of model output; run predefined iterative-prompting sensitivity tests; report interaction-severity concordance; track omissions and false-positive interaction claims; and label each finding explicitly as database-backed or model inference.
- Reference-Backed DDI Benchmark Procedure: Compare generated DDI assessments against authoritative references such as Lexicomp; evaluate interaction detection separately from severity classification and management accuracy; run and record predefined iterative-prompt variants to test answer sensitivity; and require source-backed pharmacist review before clinical use.
- Source-Grounded ASM DDI Error and Stability Workflow: For high-risk antiseizure medication combinations, compare each candidate interaction against authoritative drug references, using Lexicomp as the reference comparator and Drugs.com as a secondary comparison source; normalize severity labels and record agreement or disagreement; classify missed reference interactions as potential false negatives and unsupported model-reported interactions as potential false positives; run a predefined, bounded iterative-prompt sequence and document changes in interaction detection, severity, or recommendation; and require pharmacist review before clinical interpretation or use.
- Evidence-Backed LLM DDI Validation Workflow: Validate each LLM-generated interaction against an authoritative comparator such as Lexicomp; score severity and mechanism concordance separately; run predefined, bounded iterative prompts to test answer stability; verify that every interaction claim cites a supporting source; and mandatorily escalate conflicting, uncertain, or unsupported interactions to a pharmacist or qualified clinician.
- Pair-Level LLM DDI Evaluation Protocol: Evaluate each medication pair against Lexicomp or an equivalent pharmacist-curated reference standard; record pair-level concordance; audit severity classifications and omitted reference interactions; run predefined iterative-prompt sensitivity tests; verify that cited sources support each interaction claim; and require pharmacist review for every clinically consequential result before clinical use.
- Benchmark-Informed ASM DDI Warning: For antiseizure medication DDI use, compare LLM responses against authoritative references such as Lexicomp, use iterative prompting only as an audit aid, flag hallucinated severity or mechanism claims, and keep final interaction decisions tied to curated drug databases.
- ASM DDI Cautionary Evaluation Module: For antiseizure medication DDI comparisons informed by PubMed 41994367, set the source hierarchy before analysis, treat Lexicomp or another curated DDI database as the clinical decision reference, use Drugs.com and LLM outputs only as comparison surfaces, document iterative prompting as a pitfall-prone stability check rather than validation, re-check high-risk medication combinations against curated DDI databases, and defer clinical decisions to those curated sources plus pharmacist or qualified clinician review.
- LLM-vs-Reference ASM DDI Evaluation: For antiseizure medication DDI checks, compare LLM outputs against Lexicomp or an equivalent reference, use iterative prompting only as an assistive layer, capture severity and evidence discrepancies, and require pharmacist review before making actionable recommendations.
- High-Risk Neurology DDI Safeguard: For antiseizure and other high-risk neurology medication DDI checks, use authoritative DDI databases such as Lexicomp or Drugs.com as primary sources, treat LLM answers only as secondary explanations, log how each iterative prompt changes the interaction, severity, mechanism, or recommendation, and flag clinically significant or uncertain results for pharmacist review.
- ASM DDI Benchmark Error Classification: For antiseizure medication DDI benchmarking, compare LLM outputs against Lexicomp or another authoritative reference, document how iterative prompting changes the answer, classify severity errors and omitted reference interactions, and require pharmacist review before any patient-facing use.
- Cautionary LLM DDI Benchmarking Note: For drug-drug interaction checking, especially antiseizure medications, benchmark LLM outputs and public drug websites against Lexicomp or other curated references, require source-grounded interaction severity, capture prompt-iteration effects, and flag that neither public drug websites nor LLM outputs substitute for pharmacist review.
- Antiseizure DDI Reference-Benchmark Gate: When comparing LLM responses and Drugs.com-style outputs for antiseizure medication DDIs, use Lexicomp or another trusted reference as the benchmark, grade severity against that source hierarchy, predefine finite iterative-prompting limits, document unresolved disagreements, and require pharmacist review before clinical use.
- ASM LLM/Drugs.com-to-Lexicomp Comparison Pattern: Use antiseizure-medication DDI comparisons between LLM-assisted checks, Drugs.com, and Lexicomp as a cautionary evaluation pattern: set Lexicomp or another validated compendium at the top of the source hierarchy, treat Drugs.com and LLM outputs as comparison inputs, predefine and report iterative-prompting limits, reconcile severity discrepancies before conclusions are presented, and require pharmacist or qualified human review for discordant, uncertain, or clinically relevant results.
- PMID 41994367 ASM DDI Benchmark Lessons: For antiseizure-medication DDI benchmarking that compares LLMs and Drugs.com with Lexicomp, set Lexicomp or another validated drug-information compendium as the source-of-truth comparator, treat iterative prompting as a prompt-sensitivity pitfall rather than proof of correctness, reconcile severity labels before reporting conclusions, cite the evidence source behind each clinically relevant interaction, and require pharmacist review for discordant, uncertain, or patient-care-relevant findings.
- LLM DDI Validation Workflow Against References: Validate LLM-generated drug-drug interaction answers against authoritative references such as Lexicomp and Drugs.com, using antiseizure medications as a high-risk example; check severity classification, evidence support, and concordance or discordance across sources before accepting or escalating the answer.
- ASM DDI Safety Benchmark Gate: For antiseizure medication DDI safety benchmarks, compare LLM-generated assessments and Drugs.com outputs against Lexicomp or another validated comparator, normalize interaction severity labels before reporting agreement, treat iterative prompting as a bounded prompt-sensitivity check rather than proof of correctness, and require pharmacist or qualified clinician review before clinical interpretation.
- ASM DDI Benchmarking Control Gate: For antiseizure-medication DDI benchmarking, compare LLM outputs with reference sources such as Lexicomp and Drugs.com, predefine bounded iterative-prompting controls, report severity concordance and missing-reference-interaction checks, and hold clinically relevant, discordant, or uncertain outputs for pharmacist or qualified clinician review before use.
- ASM DDI Lexicomp/Drugs.com Benchmark Calibration: For antiseizure medication DDI benchmarking informed by PMID 41994367, compare LLM and Drugs.com outputs against Lexicomp or another validated DDI compendium, calibrate interaction severity labels before judging agreement, require citations to the source supporting each clinically relevant interaction, treat iterative prompting as a bounded sensitivity check rather than validation, and state that LLM output cannot replace authoritative DDI databases.
- ASM DDI Contraindication Validation Boundary: For antiseizure medication DDI validation informed by PMID 41994367, compare LLM answers with Lexicomp as the source-of-truth comparator and Drugs.com as a secondary comparator; normalize severity/category labels, including contraindicated or avoid-combination flags, before judging agreement; keep iterative prompting logs with each prompt, answer change, and source-comparison outcome; and require pharmacist or qualified clinician review before any contraindicated, discordant, uncertain, or patient-care-relevant result is used.
- Benchmark-Informed LLM DDI Output Gate: For LLM drug-drug interaction answers, warn that outputs must be checked against authoritative references such as Lexicomp; use iterative prompting only as an evaluation tactic for answer sensitivity; and require final structured severity, mechanism, and action recommendations to remain grounded in authoritative drug-interaction databases.
- Antiseizure-Medication DDI Benchmark Mode: For antiseizure medication DDI benchmark tasks, compare LLM outputs against authoritative references such as Lexicomp, use predefined iterative prompting controls, classify interaction severity, require citations for clinically relevant claims, and escalate discordant or high-risk interactions to pharmacist review.
- Comparative ASM DDI Benchmarking Against References: For antiseizure-medication DDI benchmarking, compare LLM-generated and Drugs.com outputs against authoritative references such as Lexicomp and Drugs.com, predefine iterative prompting analysis, reconcile interaction-severity/category labels through an explicit source hierarchy, and require pharmacist or qualified clinician review before clinical use.
- ASM DDI Lexicomp and Consumer-Reference Review Gate: For antiseizure medication DDI benchmarking, compare LLM outputs against Lexicomp as the authoritative comparator and consumer drug references such as Drugs.com only as secondary comparison sources; predefine finite iterative prompting limits and treat prompt changes as sensitivity findings, not validation; preserve contraindicated or avoid-combination flags from authoritative sources until pharmacist or qualified clinician review resolves any discordance; and require explicit clinician/pharmacist sign-off before patient-care use.
- PMID 41994367 ASM DDI Benchmarking Note: For antiseizure medication DDI benchmarking comparing LLM outputs and Drugs.com against Lexicomp, define the source-of-truth comparator before analysis, record whether iterative prompting changes interaction detection or severity labeling, preserve contraindication or avoid-combination severity labels from the comparator source, and require pharmacist review before using discordant, uncertain, or patient-care-relevant findings.
- Validated-Database Priority for ASM DDI Benchmarks: For antiseizure-medication DDI benchmarking informed by PMID 41994367, compare LLM outputs and Drugs.com findings against Lexicomp or another validated drug-interaction database, reconcile interaction-severity/category differences through the predefined source hierarchy, document iterative prompting as a pitfall-prone sensitivity check, and keep LLM outputs strictly secondary to validated DDI databases for all clinical conclusions.
- ASM DDI Lexicomp/Drugs.com Source-of-Truth Benchmark Gate: For antiseizure medication DDI benchmarking informed by PMID 41994367, compare LLM-assisted outputs and Drugs.com findings against Lexicomp or another validated source-of-truth comparator; normalize severity/category labels, including contraindicated or avoid-combination flags, before judging concordance; document bounded iterative prompting as a sensitivity caveat rather than evidence of correctness; and require pharmacist or qualified clinician review before any LLM-assisted DDI output is used clinically.
- PMID 41994367 ASM Contraindication Review Gate: When comparing LLM responses and Drugs.com findings against Lexicomp for antiseizure-medication DDIs, apply an explicit evidence hierarchy before conclusions, preserve contraindicated or avoid-combination severity labels during normalization, treat iterative prompting as an answer-drift risk rather than validation, and require pharmacist review before releasing discordant, uncertain, or patient-care-relevant results.
- ASM DDI Benchmark Extraction and Hallucination Gate: For antiseizure medication DDI benchmarking informed by PMID 41994367, compare LLM outputs and Drugs.com findings against Lexicomp under a predefined source hierarchy; set finite iterative prompting limits before testing; extract contraindication flags and severity/category labels explicitly; flag unsupported interaction, mechanism, severity, or recommendation claims as possible hallucinations; and require pharmacist or qualified clinician review for high-risk, discordant, uncertain, or patient-care-relevant interactions.
- Antiseizure Medication DDI Benchmarking Against Lexicomp: For antiseizure-medication DDI benchmarking, compare LLM answers against authoritative references such as Lexicomp, capture how iterative prompting changes interaction findings or severity/category labels, flag hallucinated or unsupported interaction severity, and require pharmacist review before clinical use.
- LLM-Generated ASM DDI Harm Review: When evaluating LLM-generated antiseizure medication DDI answers against Lexicomp or another authoritative reference, record source-specific severity/category and harm categorization, compare original and bounded iterative-prompted answers against the reference, and require pharmacist review for any clinically relevant, discordant, uncertain, or potentially harmful recommendation before use.
- PMID 41994367 ASM LLM Comparison Gate: When using LLMs for antiseizure-medication DDI assessment, compare each output with curated reference findings from Lexicomp and, when used, Drugs.com; verify interaction presence and severity/category labels before accepting summaries; treat iterative prompting as a sensitivity check rather than proof of correctness; require citations for each clinically relevant interaction; and hold discordant, uncertain, or patient-care-relevant outputs for pharmacist review.
- Antiseizure Medication DDI Safety Case: For the PubMed 41994367 benchmark comparing LLMs and Drugs.com versus Lexicomp, reconcile LLM-generated DDI advice against authoritative databases before action, analyze failures across iterative prompts, label uncertainty and source disagreement explicitly, and require pharmacist or qualified human review before using any LLM-generated DDI recommendation.
- Cautionary ASM DDI Benchmark Note: For antiseizure-medication DDI answers, treat LLM-generated and Drugs.com outputs as comparison surfaces against authoritative references such as Lexicomp; keep iterative prompting bounded and report its limits, require citations for clinically relevant interaction claims, preserve high-risk severity or contraindication flags from the reference source, and route patient-care-relevant findings to pharmacist review before use.
- LLM/Lexicomp/Drugs.com ASM DDI Comparison Workflow: For antiseizure medication drug-drug interaction checks, compare LLM output and Drugs.com findings against Lexicomp or another authoritative interaction reference, predefine and document iterative prompting steps as caveats rather than validation, reconcile interaction severity/category differences through the source hierarchy before conclusions are presented, and require pharmacist or qualified clinician review before clinical use.
- LLM-versus-Reference ASM DDI Evaluation Note: For antiseizure medication drug-drug interaction evaluations, compare LLM outputs to Lexicomp and Drugs.com reference findings, use iterative prompting only as an evaluation variable, flag hallucinated or omitted interaction severity, and keep final recommendations grounded in authoritative drug references.
- ASM Lexicomp/Drugs.com Benchmark Reconciliation: For antiseizure-medication DDI benchmarking informed by PMID 41994367, compare LLM and Drugs.com findings against Lexicomp under a predefined authoritative-source hierarchy, reconcile interaction severity/category differences before presenting conclusions, document bounded iterative prompting as a cautionary sensitivity analysis, and require pharmacist or qualified clinician review for discordant, uncertain, or patient-care-relevant findings.
- ASM DDI Triage-Only Benchmark Gate: For antiseizure medication DDI benchmarking comparing LLM outputs and Drugs.com against Lexicomp, treat LLM responses as triage only, verify every clinically relevant interaction against an authoritative interaction reference, log each iterative prompt and output change, and flag omitted interactions or potentially harmful recommendations for pharmacist or qualified clinician review.
- ASM DDI Authoritative-Database Check Rule: For antiseizure medication DDI benchmarking informed by PMID 41994367, compare LLM-generated outputs and Drugs.com findings against Lexicomp under an explicit source hierarchy; map contraindication or avoid-combination labels into the severity/category comparison before reporting agreement; treat iterative prompting as a bounded sensitivity caveat, not validation; flag uncertainty, source discordance, unsupported claims, and missing reference interactions; and never rely on LLM-generated DDI output unless it has been checked against authoritative drug databases.
- Antiseizure LLM DDI Clinical Decision Boundary: For antiseizure-medication DDI evaluations comparing LLM outputs with Lexicomp, Drugs.com, or similar references, require severity concordance checks, source citations for clinically relevant claims, and documented finite iterative prompting limits; treat prompt revisions as risk signals rather than validation, and never use an LLM as the sole source for clinical DDI decisions.
- ASM DDI Lexicomp/Drugs.com Clinical-Use Gate: For antiseizure-medication DDI benchmarking informed by PMID 41994367, compare LLM outputs and Drugs.com findings against Lexicomp using a predefined source hierarchy; set finite iterative-prompting limits before testing; normalize severity/category labels, including contraindicated or avoid-combination flags; and require citations from authoritative interaction databases before any clinical use.
- LLM-vs-Reference ASM DDI Evaluation Pattern: For antiseizure-medication DDI evaluation, compare LLM-generated answers and Drugs.com-style outputs against Lexicomp or a similar authoritative gold-standard DDI database; record iterative prompting changes in interaction detection, severity classification, and recommendations; use antiseizure medication examples as high-risk test cases; and explicitly warn that LLMs and consumer-facing references must not replace authoritative DDI databases or pharmacist/qualified clinician review.
- PMID 41994367 ASM DDI Benchmarking Caveat: For antiseizure-medication drug-drug interaction benchmarking informed by the 2026 cross-sectional comparison of large language models and Drugs.com versus Lexicomp, reconcile LLM and Drugs.com outputs against authoritative sources before conclusions, document iterative prompting as a caveat rather than proof of correctness, and explicitly warn against relying on LLM-only interaction calls.
- Antiseizure Medication DDI Comparative Source Gate: For antiseizure-medication DDI evaluations comparing LLMs, Drugs.com, and Lexicomp, set Lexicomp or another authoritative drug reference as the highest-priority source, use Drugs.com and LLM outputs only as comparison inputs, predefine finite iterative-prompting limits, log discrepancies in interaction presence, severity/category, mechanism, and recommendation across sources, and ground final interaction summaries in authoritative drug references rather than model consensus.
- PubMed 41994367 Cautionary ASM DDI Evaluation Case: Use the 2026 cross-sectional comparison of LLMs and Drugs.com versus Lexicomp for antiseizure-medication DDIs as a cautionary evaluation case; require authoritative DDI database grounding before medication-interaction advice, label severity/category and evidence source explicitly, document iterative prompting limitations, and require pharmacist review before clinical use.
- ASM DDI Cautionary Comparator Pattern: Use the PubMed 41994367 comparison of LLMs and Drugs.com versus Lexicomp for antiseizure-medication DDIs as a cautionary evaluation pattern: predefine finite iterative prompting limits, compare outputs against the reference standard rather than model consensus, record unresolved source disagreements, classify severity/category labels explicitly, and require pharmacist or qualified clinician review before clinical use.
- Antiseizure DDI Benchmarking Against Curated Sources: For antiseizure-medication drug-drug interaction benchmarks informed by PMID 41994367, compare LLM output and Drugs.com findings against Lexicomp or another curated interaction database using an explicit source hierarchy; document iterative-prompting limits and caveats; reconcile severity/category disagreements without relying on model consensus; and warn that LLM output cannot replace curated interaction databases or pharmacist/qualified clinician review.
- Cautionary LLM-Assisted ASM DDI Evaluation: For antiseizure-medication interaction checks, treat LLM-assisted outputs as comparison drafts only; compare findings against authoritative references such as Lexicomp, record how iterative prompting changes interaction detection or severity/category labels, require provenance for each interaction severity statement, and prohibit uncited LLM output from substituting for pharmacist review.
- ASM DDI Lexicomp/Drugs.com Field Reconciliation: For antiseizure medication DDI evaluation, compare LLM output and Drugs.com findings against Lexicomp or another validated DDI database, reconcile source disagreements through the authoritative database hierarchy, extract severity, onset, and action/management fields separately, log whether bounded iterative prompts drift in interaction detection or field values, and never provide autonomous medication advice without pharmacist or qualified clinician review.
- Antiseizure DDI Database Verification Gate: Use the 2026 comparison of LLMs and Drugs.com versus Lexicomp for antiseizure medication DDIs as evidence that LLM DDI outputs must be checked against authoritative drug databases, tested for iterative-prompt sensitivity, labeled with uncertainty when sources disagree, and routed to pharmacist review for high-risk anticonvulsant interactions.
- LLM-Assisted ASM DDI Reference Check: Evaluate LLM-assisted antiseizure medication DDI checks against authoritative references such as Lexicomp and Drugs.com; reconcile interaction presence and severity/category labels before reporting; document bounded iterative prompting as a caveat rather than validation; and require pharmacist or qualified clinician review before any clinical use.
- PMID 41994367 ASM DDI Benchmarking Requirement: For antiseizure-medication drug-drug interaction benchmarking, compare LLM outputs and Drugs.com findings against Lexicomp; record iterative prompting analysis and severity-class agreement or disagreement; require source-grounded interaction, severity/category, mechanism, and recommendation fields; and explicitly warn that LLM outputs must not replace curated interaction databases or pharmacist/qualified clinician review.
- ASM DDI Severity Extraction and Contraindication Escalation: For antiseizure-medication DDI benchmarking against Lexicomp and Drugs.com, set the source-of-truth hierarchy before extraction, treat Lexicomp or another validated DDI compendium as the benchmark comparator, extract interaction severity/category and contraindication or avoid-combination flags as explicit fields, document iterative prompting as a bounded caveat rather than validation, and require pharmacist review for every discordant output before clinical use.
- LLM-Assisted ASM DDI Benchmarking Review: For antiseizure medication DDI checks, benchmark LLM-assisted and Drugs.com-style outputs against authoritative references such as Lexicomp, predefine finite iterative prompting limits before comparison, reconcile severity/category discrepancies explicitly, and require pharmacist or qualified clinician review before any clinical use.
- ASM Lexicomp/Drugs.com DDI Evaluation Gate: For antiseizure-medication DDI evaluations comparing LLM outputs or Drugs.com findings against Lexicomp, require source-grounded interaction severity and dose/context qualifiers for each clinically relevant interaction, document finite iterative-prompting caveats and any changed answers, and enforce a hard rule that LLM outputs cannot replace authoritative DDI databases or pharmacist/qualified clinician review.
- ASM LLM/Drugs.com/Lexicomp Benchmark Review Gate: For antiseizure-medication DDI benchmarking, compare LLM-generated outputs and Drugs.com findings against Lexicomp, record iterative prompting effects without treating them as validation, harmonize severity/category labels before agreement scoring, require citations for each clinically relevant interaction claim, and hold discordant, uncertain, or patient-care-relevant results for pharmacist review.
- PMID 41994367 Comparative ASM DDI Benchmarking Guidance: For antiseizure medication DDI benchmarking based on the 2026 cross-sectional comparison of LLMs and Drugs.com versus Lexicomp, compare LLM and Drugs.com outputs against Lexicomp as the reference-standard comparator, stratify interaction presence and severity/category agreement explicitly, document unresolved reference-standard disagreements without relying on model consensus, treat bounded iterative prompting as a caveat-sensitive analysis step rather than proof of correctness, and require pharmacist or qualified clinician review before any clinical use.
- LLM ASM DDI Evaluation Stress Test: Use antiseizure medication DDI cases as a stress test for LLM-assisted interaction evaluation; compare each LLM answer and any Drugs.com result against Lexicomp or another validated reference, classify severity/category under the predefined evidence-source hierarchy, document finite iterative prompting caveats and answer changes, and require pharmacist or qualified clinician review before clinical use.
- ASM DDI False-Reassurance and Citation Gate: For antiseizure medication DDI evaluations, compare LLM outputs and Drugs.com-style findings against curated interaction references such as Lexicomp; normalize severity/category labels before reporting; treat iterative prompting as an answer-drift risk requiring checks for omitted interactions, unsupported "no interaction" reassurance, missing contraindication or avoid-combination flags, and uncited management advice; cite the curated reference supporting each clinically relevant interaction; and require pharmacist or qualified clinician review before clinical use.
- ASM DDI Lexicomp/Drugs.com Benchmark Routing: For antiseizure-medication DDI benchmarking, compare LLM outputs and Drugs.com findings against Lexicomp under a predefined iterative prompting protocol; record severity/category concordance and discordance; flag false reassurance risks such as unsupported "no interaction" statements or missing contraindication/avoid-combination warnings; and route high-risk, discordant, or uncertain DDI outputs back to authoritative databases before pharmacist or qualified clinician review.
- Comparative ASM LLM/Drugs.com Evidence Check: Apply PMID 41994367 as comparative evidence for antiseizure-medication DDI evaluation by checking LLM outputs and Drugs.com findings against Lexicomp or another authoritative interaction database; treat iterative prompting as secondary prompt-sensitivity analysis only, never as a substitute for authoritative database verification or clinical pharmacy review.
- PMID 41994367 ASM DDI Review Gate: For antiseizure-medication DDI evaluations comparing LLM outputs with Drugs.com and Lexicomp, require citations for each clinically relevant interaction claim, predefine and report finite iterative prompting limits, reconcile severity/category disagreements across sources before presenting conclusions, and hold discordant, uncertain, or patient-care-relevant findings for pharmacist or qualified clinician review.
- Clinical LLM DDI Benchmarking Module: Benchmark LLM-generated drug interaction assessments against Lexicomp or a similar pharmacist-vetted reference by normalizing each medication pair before comparison, including antiseizure-medication edge cases, auditing bounded iterative prompting changes, grading severity and actionability separately, and enforcing that LLM output must not replace authoritative interaction databases.
- ASM LLM/Drugs.com Benchmark Escalation Rule: When benchmarking antiseizure-medication DDI outputs against Lexicomp as in PMID 41994367, compare LLM and Drugs.com results pair-by-pair, normalize severity/category labels before agreement scoring, preserve contraindicated or avoid-combination flags as escalation triggers, treat iterative prompting as bounded sensitivity analysis with predefined limits rather than validation, fall back to authoritative DDI databases for final calls, and require pharmacist or qualified clinician review before patient-care use.
- Warning-Oriented LLM-Assisted ASM DDI Review: For antiseizure medication drug-drug interaction reviews comparing LLM-assisted output with Lexicomp and Drugs.com, require source-grounded interaction lookup before accepting any finding, use iterative prompting only as an adjunct prompt-sensitivity check, reconcile severity/category differences across sources, and require pharmacist review before any clinical recommendation.
- LLM-versus-Reference DDI Validation: Validate LLM-generated DDI answers against Lexicomp or an equivalent curated database as the ground truth, using antiseizure-medication examples when relevant; compare interaction presence and severity classification, require citations for clinically relevant claims, document bounded iterative-prompting caveats and answer changes, and require pharmacist review before clinical use.
- LLM-vs-Authoritative DDI Benchmarking: When benchmarking LLM drug-drug interaction output against Lexicomp and Drugs.com comparators, extract interaction presence, severity/category, and management recommendations as separate fields; run predefined finite iterative prompting checks and record any answer changes; require provenance for each clinically relevant claim; and enforce that LLM output can never override authoritative interaction databases.
- PMID 41994367 ASM Medication-Safety Benchmark Gate: For antiseizure-medication DDI benchmarking comparing LLM responses and Drugs.com-style outputs against Lexicomp or another trusted reference, classify interaction presence and severity/category explicitly, require citations for each clinically relevant claim, document finite iterative-prompting limits and answer changes as cautions rather than validation, and apply hard stops when authoritative references are missing, severity cannot be reconciled, or any patient-care-relevant result remains unsupported, discordant, or unreviewed by a pharmacist or qualified clinician.
- PMID 41994367 ASM Lexicomp/Drugs.com Benchmark Check: For antiseizure medication DDI benchmarking, compare LLM outputs and Drugs.com findings against Lexicomp under a predefined source-of-truth hierarchy; normalize interaction severity/category labels before agreement scoring or summaries; document iterative prompting variability as a prompt-sensitivity warning rather than validation; and require pharmacist or qualified clinician review before any clinical use.
- LLM-vs-Reference ASM DDI Evaluation Mode: For antiseizure medication interactions, evaluate generated answers against Lexicomp or Drugs.com-style references; track prompt iteration effects on interaction detection, severity/category agreement, omissions, and recommendations; and trigger pharmacist or qualified clinician review for omitted, discordant, uncertain, or patient-care-relevant findings.
- Cautionary ASM LLM DDI Review: For antiseizure medication DDI answers, compare LLM-generated content against trusted references such as Lexicomp and Drugs.com, document finite iterative prompting limits and unresolved disagreements, escalate high-risk or clinically consequential interaction findings, and require pharmacist or qualified clinician review before clinical use.
- PMID 41994367 ASM Lexicomp/Drugs.com Benchmarking Rule: For antiseizure medication DDI benchmarking, compare LLM and Drugs.com outputs against Lexicomp or another validated drug-interaction database under a predefined source hierarchy; set and report finite iterative prompting limits; reconcile interaction severity/category labels before reporting agreement or disagreement; and defer clinical decisions to validated drug-interaction databases plus pharmacist or qualified clinician review.
- LLM-versus-Reference DDI Evaluation Workflow: For antiseizure medication examples, benchmark LLM-generated interaction answers and Drugs.com-style outputs against Lexicomp or another validated DDI database; log each iterative prompt, response revision, and comparison result; score interaction presence and severity/category agreement explicitly; and warn that LLM output cannot replace validated interaction databases or pharmacist/qualified clinician review.
- Medication-Safety Benchmarking for LLM-Assisted DDI Review: Compare LLM-assisted drug-drug interaction outputs against authoritative references such as Lexicomp, include antiseizure medication examples when relevant, preserve iterative prompting logs, classify severity disagreements explicitly, and require pharmacist or qualified clinician review before any recommendation is used.
- Lexicomp and Drugs.com Comparison Caution: Apply the 2026 PubMed-reported cross-sectional comparison of LLMs and Drugs.com versus Lexicomp for antiseizure medication DDIs as cautionary evidence: set a source hierarchy before review, treat Lexicomp or another validated interaction reference as the comparator, use Drugs.com and LLM output only as comparison inputs, document finite iterative prompting limits and unresolved prompt-driven changes, and require pharmacist or qualified clinician verification before clinical use.
- Antiseizure DDI LLM/Drugs.com/Lexicomp Validation Case: Use the PubMed 41994367 antiseizure medication DDI comparison as a validation case by defining the source hierarchy before review, comparing LLM and Drugs.com outputs against Lexicomp or another pharmacist-reviewed reference, documenting iterative prompting as a prompt-sensitivity risk rather than proof of correctness, reconciling source discrepancies in interaction presence and severity/category before conclusions, and escalating discordant, uncertain, or patient-care-relevant findings to pharmacist-reviewed references and pharmacist or qualified clinician review.
- Antiseizure DDI Expert-Reference Evaluation: For antiseizure medication DDI evaluations, benchmark LLM-generated and consumer drug-reference outputs against Lexicomp-style expert references, test whether bounded iterative prompting changes interaction presence, severity/category, mechanism, or recommendation, flag high-risk interaction classes identified by the benchmarked references, and require pharmacist or qualified clinician review before recommendations are surfaced.
- Antiseizure DDI Lexicomp/Drugs.com Benchmark Verification: For antiseizure-medication DDI benchmarking informed by PMID 41994367, compare LLM outputs and Drugs.com findings against Lexicomp under a predefined source hierarchy; normalize interaction severity/category labels before scoring agreement or presenting conclusions; document iterative prompting as a pitfall-prone sensitivity check, including answer changes and unresolved discrepancies; check for hallucinated, unsupported, or omitted interaction claims; and require clinician or pharmacist verification before any patient-facing recommendation.
- ASM DDI LLM Safety Benchmark: Use the 2026 PubMed cross-sectional comparison of LLMs and Drugs.com versus Lexicomp for antiseizure medication DDIs as a safety benchmark: define the source hierarchy before review, compare LLM-assisted and Drugs.com outputs against Lexicomp, categorize interaction severity explicitly, document finite iterative prompting limits and unresolved prompt-driven changes, and require pharmacist or qualified clinician verification before clinical use.
- ASM LLM/Public-Source Lexicomp Safety Frame: In antiseizure medication DDI review, frame LLM outputs and public drug-information sources such as Drugs.com as comparison inputs against Lexicomp; set Lexicomp as the top source in the hierarchy, document bounded iterative-prompting changes as risk signals, require specialist pharmacist review for discordant, uncertain, or patient-care-relevant findings, and state explicitly that LLMs and public sources do not substitute for Lexicomp in clinical DDI decisions.
- ASM DDI Benchmarking vs Drugs.com and Lexicomp: For antiseizure medication DDI benchmarking informed by PMID 41994367, compare LLM outputs and Drugs.com results against Lexicomp or another validated DDI reference as the source-of-truth comparator; set finite iterative prompting limits before review; document contradictions across sources without letting repeated prompts overrule the source hierarchy; escalate high-risk, discordant, or uncertain interactions; and require pharmacist or qualified clinician review before clinical use.
- Antiseizure DDI LLM Warning Case: Use PMID 41994367 as a warning case for LLM-based antiseizure-medication DDI checking by setting the source hierarchy before output generation, treating Lexicomp or another validated compendium as the reference comparator, Drugs.com as secondary comparison input, and LLM content as an unvalidated draft; predefine finite iterative prompting limits, preserve contraindication or avoid-combination severity flags as escalation triggers, and release only pharmacist-reviewed outputs.
- LLM DDI Evaluation Guardrail: Use antiseizure medication DDIs as a stress test for LLM-assisted interaction checks; compare outputs against Lexicomp-style authoritative references, record how prompt iterations change interaction presence, severity/category, mechanism, or recommendation, flag disagreements with public sources such as Drugs.com, and require pharmacist or qualified clinician review before clinical use.
- LLM-vs-Reference ASM DDI Benchmark Review: For antiseizure medication DDI benchmarking, compare LLM-generated findings and Drugs.com results with Lexicomp or another validated DDI reference before reporting conclusions; score interaction presence and severity/category concordance separately; treat iterative prompting as a pitfall-prone sensitivity check that can introduce answer drift rather than proof of correctness; flag hallucinated, unsupported, or omitted interactions; and require pharmacist or qualified clinician review before any patient-care use.
- PMID 41994367 ASM DDI Cautionary Benchmark: Treat the 2026 PubMed-reported antiseizure medication DDI comparison of LLMs and Drugs.com versus Lexicomp as a cautionary benchmark for LLM drug-interaction workflows: set Lexicomp as the comparator in the source hierarchy, use Drugs.com and LLM outputs as comparison inputs, reconcile interaction severity/category differences before reporting, document finite iterative-prompting limits and unresolved prompt-driven changes, and require pharmacist or qualified clinician review before clinical use.
- ASM Consumer-Reference Benchmarking and Escalation: For antiseizure medication DDI benchmarking, compare LLM outputs and consumer drug-reference findings, including Drugs.com when used, against Lexicomp-style authoritative compendia; predefine finite iterative prompting limits and log answer changes; calibrate interaction severity/category labels to the authoritative comparator before reporting; require citations for each clinically relevant claim; and refuse patient-specific clinical recommendations or escalate to pharmacist or qualified clinician review when evidence is uncertain, unsupported, discordant, or not citation-verifiable.
- LLM-versus-Reference DDI Evaluation Workflow: For antiseizure-medication examples, evaluate LLM-generated interaction answers against Lexicomp or Drugs.com-style references by comparing each medication pair for interaction presence, severity/category, management recommendation, and cited evidence; log a predefined finite iterative prompting sequence with each response revision; score source agreement or disagreement explicitly; require citations for clinically relevant claims; and warn that general LLMs are not authoritative DDI checkers and cannot replace validated references or pharmacist/qualified clinician review.
- PMID 41994367 ASM DDI Benchmark Review Gate: For antiseizure-medication DDI benchmarking, compare LLM outputs against Lexicomp as the reference comparator and Drugs.com-style outputs as comparison inputs; classify interaction presence and severity/category explicitly; require citations for each clinically relevant claim; document finite iterative-prompting limits and answer changes as cautionary rather than validating; and hold discordant, unsupported, or patient-care-relevant findings for pharmacist or qualified clinician review before use.
- Antiseizure LLM DDI Evaluation Path: For antiseizure-medication DDI evaluations, compare LLM responses against Lexicomp or Drugs.com references; run bounded iterative prompt-sensitivity checks; label severity and actionability separately; capture the proposed interaction mechanism; and require pharmacist verification before any clinical use.
- ASM LLM-versus-Reference Contraindication Gate: For antiseizure-medication DDI benchmarking informed by PMID 41994367, compare LLM outputs and Drugs.com findings with Lexicomp as the reference comparator, document finite iterative-prompting limits and unresolved answer changes, preserve contraindication or avoid-combination severity labels as escalation triggers, and require pharmacist or qualified clinician review before clinical use.
- LLM-vs-Lexicomp ASM DDI Benchmark Pattern: For antiseizure-medication DDI benchmarks comparing LLM output and Drugs.com-style results with Lexicomp, predefine finite iterative-prompting controls; score interaction presence, severity/category, and actionability or management advice separately under a source hierarchy that treats Lexicomp or another validated DDI compendium as the comparator, Drugs.com as secondary comparison, and LLM content as an unvalidated draft; check for false reassurance such as unsupported no-interaction conclusions, omitted reference interactions, or downplayed severity; and require pharmacist or qualified clinician review before any patient-facing or clinical recommendation.
- Antiseizure DDI Validation Warning: For antiseizure-medication DDI outputs, benchmark LLM answers against authoritative interaction databases such as Lexicomp and compare Drugs.com as a reference comparator; test and document iterative prompting effects; flag unsupported severity/category claims; and require pharmacist or qualified clinician review before any DDI output is used clinically.
Medication-Safety Benchmarking for LLM-Assisted DDI Review
For LLM-assisted drug-drug interaction review, treat model output as a draft benchmarked against authoritative references such as Lexicomp. Include antiseizure medication examples when relevant, retain iterative prompting logs, classify severity disagreements between sources, and block any recommendation from use until reviewed by a pharmacist or qualified clinician.
Comparative Benchmark: LLM-Based ASM DDI Checks
LLM-generated DDI findings are screening drafts, not standalone clinical evidence. For antiseizure medication benchmarks, compare each generated answer and any Drugs.com output against authoritative databases such as Lexicomp; document prompts and finite iteration limits; classify severity explicitly; record unresolved disagreements without resolving them by model consensus; and route outputs to pharmacist review before clinical use.
Safety Benchmark: LLM vs Lexicomp/Drugs.com ASM DDIs
Use PubMed PMID 41994367 as a cautionary evaluation pattern for antiseizure medication drug-drug interactions, not as a standalone performance guarantee. Apply this source hierarchy before analysis: Lexicomp or another validated DDI compendium as the benchmark comparator, Drugs.com as a secondary comparison source, and LLM output as an unvalidated draft. Normalize severity/category labels across sources before reporting concordance or discordance; predefine and log finite iterative prompts as prompt-sensitivity checks; and block clinical release until a pharmacist or qualified clinician reviews discordant, uncertain, or patient-care-relevant findings.
Antiseizure-Medication DDI Benchmarking
Use the 2026 cross-sectional ASM DDI comparison as a prompt-sensitivity and reference-alignment check. Compare LLM answers against authoritative references such as Lexicomp, include Drugs.com only as a comparison surface when available, record prompt-iteration effects on interaction detection and severity/category labeling, flag hallucinated or unsupported severity claims, and require pharmacist review before clinical use.
Evaluation and Prompting
- Establish the source hierarchy before evaluation: use a validated interaction database such as Lexicomp as the authoritative comparator, use Drugs.com as a secondary comparison source, and treat LLM output as unvalidated.
- Compare severity and mechanism agreement separately across sources, and record omissions as potential false negatives requiring review.
- Run a predefined, bounded sequence of iterative prompts and record whether each iteration changes the identified interaction, severity, mechanism, or recommendation.
- Do not interpret prompt-to-prompt agreement or improvement as validation. Never substitute LLM output for Lexicomp or another validated interaction database.
LLM-Assisted DDI Evaluation
Use PMID 41994367 as a cautionary evaluation pattern for antiseizure-medication drug-drug interaction checks. Treat LLM output as a draft to compare with authoritative references such as Lexicomp and Drugs.com; record source-specific interaction presence, severity/category, mechanism, and recommendation fields; reconcile severity/category differences through the predefined source hierarchy; document finite iterative prompting steps and answer changes as caveats rather than proof of correctness; and require pharmacist or qualified clinician review before any patient-care-relevant use.
LLM DDI Evaluation: Antiseizure Stress Test
Use antiseizure medication DDI examples as a high-risk stress test when evaluating LLM-assisted interaction answers. Compare LLM output and Drugs.com findings with Lexicomp or another validated DDI reference; classify interaction severity/category from the source hierarchy; document any bounded iterative prompting steps as caveats, including changed or unresolved answers; and require pharmacist or qualified clinician review before using conclusions in patient care.
LLM-versus-Reference DDI Validation
Use Lexicomp or an equivalent curated DDI database as the ground-truth comparator for LLM-generated interaction answers, with antiseizure-medication cases as the example context from PMID 41994367. Compare LLM and Drugs.com-style outputs pair-by-pair against the curated reference; record interaction presence, severity/category classification, cited source, and any change caused by finite iterative prompting; treat iterative prompting as a caveat, not validation; and require pharmacist review before clinical use.
Cautionary Evaluation: ASM DDIs
For antiseizure medication drug-drug interaction answers, treat LLM output as an unvalidated draft and compare it with trusted references such as Lexicomp and Drugs.com before reporting conclusions. Iterative prompting may be documented as a bounded limitation or sensitivity check, but it must not replace source comparison. Escalate high-risk, discordant, uncertain, or patient-care-relevant interactions for pharmacist or qualified clinician review.
Workflow
- Input: List of drug names (e.g., "Warfarin, Aspirin").
- Analysis: Queries internal interaction database.
- Output: Interaction report with severity and mechanisms.
Example Usage
User: "Check interactions for Warfarin and Aspirin."
Agent Action:
python3 Skills/Pharma/Drug_Interaction/impl.py --drugs "Warfarin, Aspirin"
References
